Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Leases (2021 - 2025)

InMed Pharmaceuticals' Current Leases history spans 5 years, with the latest figure at $408122.0 for Q4 2025.

  • For Q4 2025, Current Leases fell 2.76% year-over-year to $408122.0; the TTM value through Dec 2025 reached $408122.0, down 2.76%, while the annual FY2025 figure was $435507.0, 37.04% up from the prior year.
  • Current Leases reached $408122.0 in Q4 2025 per INM's latest filing, down from $424765.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $435507.0 in Q2 2025 to a low of $82232.0 in Q3 2021.
  • Average Current Leases over 5 years is $375450.9, with a median of $404219.5 recorded in 2022.
  • Peak YoY movement for Current Leases: skyrocketed 391.49% in 2022, then dropped 27.5% in 2023.
  • A 5-year view of Current Leases shows it stood at $391805.0 in 2021, then increased by 5.74% to $414307.0 in 2022, then dropped by 12.1% to $364190.0 in 2023, then rose by 15.25% to $419711.0 in 2024, then fell by 2.76% to $408122.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Current Leases are $408122.0 (Q4 2025), $424765.0 (Q3 2025), and $435507.0 (Q2 2025).